Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track

Executive Summary

Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.

You may also be interested in...



Start-up QED Touts Singular Focus On FGFR Inhibitor Infigratinib

Emerging Company Profile: With backing from BridgeBio, San Francisco start-up QED sees potential for drug licensed from Novartis in a number of tumor types, following the recent presentation of promising results in Phase II for bile duct cancer and Phase I for advanced urothelial cancer.

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.

Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition

Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel